Search

El objetivo de este estudio fue analizar las características de los pacientes con melanoma tratados a nivel hospitalario, evaluar los datos de incidencia y mortalidad de la enfermedad, y calcular los

BCN HEALTH realizó un estudio retrospectivo basado en los registros de pacientes hospitalizados por NAFLD/NASH y tratados en hospitales públicos y privados españoles entre enero de 2006 y abril de

59% of drugs (277 lines of research at national companies and multinational corporations with a subsidiary in Spain) focus on finding a treatment for cancer

Microalgae, fungi, worms and by-products are some alternative proteins that are coming to our plates. We spoke with some companies to hear about the main benefits and their long-term vision

For World Environmental Education Day, we spoke with four of the 70 Spanish ambassadors working to raise awareness, particularly among the younger generation, about climate change and its consequences

“Merck Survey: Europeans' perception of health two years after the start of Covid 19” carried out in 10 countries across Europe Almost a quarter of Europeans say they have reduced their alcohol and

Increase in capital is set to 3.5 million euros with a discount of 10% on a valuation of 20 million euros. It coincides with the end of recruitment for the clinical trials for its drug to treat

In three months, biotechnology company Neurofix will have the first results of phase IIa of NFX88 and will be able to begin phase IIb/III towards the end of the year

The ADvantage study, whose principal investigator and coordinator is Professor Richard Warren of the University of Manchester, began in July 2021 after being submitted to the ethics committees of 80

ABTL0812 is administered in combination with FOLFIRINOX in a double blind, randomized and placebo controlled clinical trial The University of Cincinnati Medical Center (Cincinnati, OH, EEUU) and the

DIVERSA is an early-stage biotech and drug delivery company founded in 2022 in Santiago de Compostela (Spain) and offers a novel patented nanotechnology based on non-toxic, biodegradable lipids.

The spin-off from VHIO (Vall d'Hebron Institute of Oncology) and ICREA – Peptomyc – has developed the first oncological treatment based on MYC inhibition,

Mutagenicity (capacity to alter cellular genetic material) is one of the most important parameters for evaluating the possible toxicity of chemical products, particularly during their mandatory